NEW YORK – Advanced Genomics APAC and 3BIGS announced on Wednesday a strategic partnership focused on bringing advanced cancer genomic testing services to the Asia-Pacific market.
The collaborators will develop cancer gene panels and bioinformatics pipelines for clinicians and researchers, bringing cancer diagnostic services tailored to the Asia-Pacific region's needs. The two firms will integrate Advanced Genomics' Nonacus GALEAS comprehensive tumor genomic profiling platform with 3BIGS's bioinformatics and data analysis capabilities.
Financial and other details of the partnership were not disclosed.
"This partnership represents a significant milestone for Advanced Genomics APAC, as we continue to expand our footprint in the Asia-Pacific region," Andy Chang, director of Advanced Genomics APAC, said in a statement. "By leveraging the strengths of both companies, we aim to accelerate access to cutting-edge cancer diagnostics and support clinicians in delivering personalized treatment strategies."
Earlier this year, Advanced Genomics APAC signed a memorandum of understanding with CancerFree Biotech aimed at forging a partnership to develop personalized treatment plans for cancer patients via next-generation sequencing and in vitro drug testing.